Kobayashi Pharmaceutical | Sustainability Performance

https://www.kobayashi.co.jp/english/

Produces healthcare, household, and personal care products.

1919

Japan

1,001 - 5,000 employees

Pharmaceuticals

$1B - 10B in revenue

$100M - 500M in profitability

Submit or report inaccurate data Download Company Insights

Sustainability Ranking & Industry Benchmark

#4170

Overall

#184

in Japan

#93

in Pharmaceuticals

Sustainability Maturity

Sustainability Intent

Available in
Scale package

Access

Industry Rank

97 out of 312

Overview

Environmental

Carbon emissionsWater managementNature and biodiversityNature riskClimate risk

Social

Diversity and inclusionPay gapsExternalities

Governance

TargetsSDG ImpactESG scores and exclusionsB-corp & CDP

Financial Data

Business performanceCapital & innovationAnalyst projections

View similiar companies

Rici Healthcare

Japan, Hospital & Health Care, Hospital & Health Care

Santen Pharmaceutical

Japan, Hospital & Health Care, Pharmaceuticals

Takeda Pharmaceutical

Japan, Hospital & Health Care, Pharmaceuticals

Female engagement

41% 2024

Critical

Externalities

3.0M $, 2024

Laggard

Market cap

66.3T $, 2026▲5.1% YoY

Revenue

1.1B $, 2025▲0.1% YoY

R&D intensity

5.5% 2025

Intensity

Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)

Water consumption intensity (m³ /$M)

Industry Benchmark

510.1

B/M 114.3

336.8

B/M 219.7

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Kobayashi Pharmaceutical Co Ltd, Japanese major OTC pharma, suffered the historic March 2024 'beni koji' (red yeast rice) cholesterol supplement scandal causing at least 5 deaths and over 280 hospitalizations in Japan, with massive Japanese MHLW enforcement and product recalls affecting Kobayashi's institutional shareholder governance trust and customer relationships.

Carbon emissions breakdown

Reveal data for 2 credits

KPI	Metric	Year
		2019	2020	2021	2022	2023	Benchmark
*******	*******	-	-	-	*******	*******	*******
*******	*******	-	-	-	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Biodiversity impact

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

KPI	Metric	Year
	2019	2020	2021	2022	2023	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******

Water management

Reveal data for 2 credits

KPI	Metric	Year
		2019	2020	2021	2022	2023	Benchmark
*******	*******	-	-	-	-	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	-	*******	*******
*******	*******	-	-	-	-	*******	*******
*******	*******	*******	*******	*******	*******	-	*******

Land use

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Diversity & inclusion

Reveal data for 3 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Pay gap breakdown

Reveal data for 1 credit

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	-	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Externalities

Reveal data for 1 credit

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

SBTi targets and commitments

Target	Status	Temperature alignment	Year
Near-term target	Targets set	1.5°C	2030
Long-term target	Not disclosed	-	-
Net-zero	Not disclosed	-	-
Business Ambition 1.5°C	Not disclosed	-	-

Target details

KOBAYASHI Pharmaceutical Co. , Ltd. commits to reduce absolute scope 1 and 2 GHG emissions 51% by 2030 from a 2018 base year. KOBAYASHI Pharmaceutical Co. , Ltd. also commits to reduce absolute scope 3 GHG emissions 15% within the same timeframe

SDG impact (historical)

Reveal data for 5 credits

KPI	Metric	Year
		2019	2020	2021	2022	2023	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Reporting

Sustainability Report

Available

Sustainability employees

Total sustainability employees

Available in
Scale package

Access

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Kobayashi Pharmaceutical Co Ltd, Japanese major OTC pharma, suffered the historic March 2024 'beni koji' (red yeast rice) cholesterol supplement scandal causing at least 5 deaths and over 280 hospitalizations in Japan, with massive Japanese MHLW enforcement and product recalls affecting Kobayashi's institutional shareholder governance trust and customer relationships.

Kobayashi Pharmaceutical | Sustainability Performance